Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
Open Access
- 29 August 2012
- journal article
- Published by Springer Science and Business Media LLC in Pediatric Rheumatology
- Vol. 10 (1), 30
- https://doi.org/10.1186/1546-0096-10-30
Abstract
Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab.Keywords
This publication has 7 references indexed in Scilit:
- Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6Cytokine, 2012
- MACROPHAGE ACTIVATION SYNDROMEPublished by Elsevier BV ,2011
- Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trialThe Lancet, 2008
- Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.2007
- Juvenile idiopathic arthritisThe Lancet, 2007
- Therapeutic efficacy of humanized recombinant anti–interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritisArthritis & Rheumatism, 2005
- Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvementArthritis Research & Therapy, 2005